Rosetta Biosoftware公司推出6.0版Rosetta Resolver基因表达数据分析系统

Rosetta Biosoftware公司推出6.0版Rosetta Resolver基因表达数据分析系统
www.med8th.com | 2006年3月1日

美国商业新闻2006年2月27日西雅图消息——Rosetta Biosoftware公司今天公布了6.0版Rosetta Resolver?基因表达数据分析系统，该系统具有支持毒理基因学研究的性能。新版Resolver系统将在于2006年3月5－9日在加利福尼亚州圣地亚哥举行的毒理学会年会以及ToxExpo上展示。新的6.0版Resolver系统为基因表达提供了一个综合数据管理及分析平台，可以满足所有机构的需求。

Rosetta Biosoftware公司副总裁兼总经理Yelena Shevelenko说：“6.0版Resolver系统主要是用来帮助研究人员查明先导化合物中的毒性，揭局瘟乒讨械姆肿踊硪约坝卸疚锏姆肿踊怼Ｗ钚掳姹镜腞esolver系统是通过与我们在药物开发领域里的客户进行密切合作开发出来的。我们的解决方案为客户提供了最小化成本的独特数据挖掘技巧以及时间密集型下游分析。”

Resolver系统的先进分析和数据管理解决方案使得用户可以观察毒性的表达印记，确定多重治疗中药物剂量的效果，对比从一种动物模型到另一种动物模型的毒性。Resolver系统与第三方数据库以及如GeneGo MetaCore?、Iconix DrugMatrix?和Ingenuity Pathways Analysis等内容提供应用之间的互用性给研究人员提供了揭示分子活动机理，或确定最有效治疗方案的能力。这项应用是一个全面的解决方案，确保基因表达数据分析机构之间进行最佳实践活动、遵守规定及开展协作。有关该系统的详细信息将于3月9－10日在波士顿举行的Rosetta技术论坛上提供。欲注册参加此次会议，可访问网站 www.rosettabio.com/conferences 。

Rosetta Resolver系统由Rosetta Biosoftware公司开发并提供支持，由Agilent科技公司（Agilent Technologies）独家分销。

关于Rosetta Biosoftware公司

Rosetta Biosoftware公司是面向生命科学研究的信息解决方案领先供应商。其企业软件解决方案包括Rosetta Resolver和Elucidator系统，能够为生命科学家提供先进的、可升级的和易于操作的分析平台，从而加速开展发现研究工作。Rosetta Biosoftware公司是默克公司（Merck & Co., Inc.）（纽约证券交易所：MRK）全资子公司Rosetta Inpharmatics LLC公司的下属业务单位。了解关于Rosetta Biosoftware公司的更多信息，请访问网站 http://www.rosettabio.com　。

前瞻性声明

本新闻包含1995 年《私人证券诉讼修正法案》界定的“前瞻性声明”。这些前瞻性声明具有一定的风险和不确定性，可能会导致实际结果与这些前瞻性声明所述的结果产生重大差别。这些前瞻性声明可能包括有关产品开发、产品潜力或者财务业绩的表述。任何前瞻性声明都不能被保证，实际的结果可能会与计划的内容大不相同。无论出现新信息、未来事件，还是出现其他情况，Rosetta Inpharmatics公司和默克公司都不承担公开更新任何前瞻性声明的义务。本新闻中的前瞻性声明应同影响默克公司业务的不确定因素一起加以评估，其中包括：Rosetta Inpharmatics公司的技术平台在药物研究计划中的应用程度、Rosetta Inpharmatics公司的技术在市场上接受程度的不确定性、同现有技术的竞争力以及默克公司在2004年12月31日结束年度的10-K表格中第一项的警示声明所提及的内容，以及可以一起作参考的有关10-Q表格及8-K表格（如有的话）定期报告中所提及的内容。

Rosetta Resolver和Rosetta Elucidator是Rosetta Inpharmatics LLC公司在美国的注册商标。

联系方式：Rosetta Biosoftware公司 Lisa Owen, 206-926-1236

(BW)(WA-ROSETTA-BIOSOFTWARE)(MRK) Rosetta Biosoftware Introduces the Rosetta Resolver Gene Expression Data Analysis System Version 6.0

SEATTLE--(BUSINESS WIRE)--Feb. 27, 2006--

Rosetta Biosoftware today introduced the Rosetta Resolver(R) gene expression data analysis system 6.0, with capabilities to support toxicogenomics research. The new version of the Resolver system will be presented at the Society of Toxicology annual meeting and ToxExpo in San Diego, California, March 5 to 9, 2006. The new Resolver system 6.0 provides a comprehensive data management and analysis platform for gene expression that can scale to fit the needs of any organization.

"The Resolver system version 6.0 is designed to aid researchers in pinpointing toxicity in lead compounds and uncovering molecular mechanisms of treatments and toxicants," said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware. "The latest version of the Resolver system was developed through close work with our customers involved in drug development. Our solution provides customers with unique data mining techniques to minimize costly and time-intensive downstream analysis."

The Resolver system's advanced analysis and data management solution enables users to observe expression signatures of toxicity, determine dose effects across multiple treatments, and compare toxicity from one animal model to another. The interoperability of the Resolver system with third-party databases and content-providing applications, such as GeneGo MetaCore(TM), Iconix DrugMatrix(TM), and Ingenuity Pathways Analysis, give researchers the ability to uncover molecular mechanisms of action or determine pathways most impacted by treatments. The application serves as a comprehensive solution for ensuring best practices, regulatory compliance, and collaboration for cross-organization analysis of gene expression data. Further information about the system will be presented at the upcoming Rosetta Technology Forum in Boston on March 9 and 10. To register for this conference, visit www.rosettabio.com/conferences.

The Rosetta Resolver system is developed and supported by Rosetta Biosoftware, and is distributed exclusively by Agilent Technologies.

About Rosetta Biosoftware

Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its enterprise software solutions, including the Rosetta Resolver and Elucidator systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. (NYSE:MRK). More information about Rosetta Biosoftware is available at www.rosettabio.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics' technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics' technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2004, and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference.

Rosetta Resolver and Rosetta Elucidator are U.S. registered trademarks of Rosetta Inpharmatics LLC.

CONTACT: Rosetta Biosoftware Lisa Owen, 206-926-1236